what makes retatrutide different vs. Tirzepatide: The Next-Gen GLP-1 Showdown Retatrutide vs Semaglutide and Tirzepatide:

Tirzepatide (a GLP-1R/GIPR dual agonist), licensed by the MHRA as Mounjaro for type 2 diabetes and, subject to NICE guidance, for weight management in adults with obesity, achieved mean weight reductions of up to approximately 22% in the SURMOUNT-1 trial (NEJM 2022) a notable improvement over GLP-1R monotherapy

[DOI] [PubMed] [Google Scholar] 35.Mayo KE, Miller LJ, Bataille D, et al

The study recruited participants through endometriosis advocacy platforms, social media, and clinical networks, targeting women aged 18 to 55 with confirmed or suspected endometriosis and current or prior GLP-1 medication use

Your provider should screen for these factors before initiating GLP-1 therapy